| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | NID-2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human NID2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于NID2抗体的3篇文献概览：
---
1. **文献名称**：*DNA methylation of NID2 as a potential biomarker for early detection of colorectal cancer*
**作者**：Wu et al.
**摘要**：研究探讨了NID2基因启动子区甲基化在结直肠癌患者血液中的检测价值，发现其甲基化水平显著高于健康对照组，提示其作为无创诊断标志物的潜力。
2. **文献名称**：*Nidogen-2 expression in tumor stroma: A novel prognostic marker for invasive breast cancer*
**作者**：Mund et al.
**摘要**：通过免疫组化分析乳腺癌组织中NID2蛋白的表达，发现基质细胞中NID2高表达与患者生存率降低相关，表明其在肿瘤微环境中的促转移作用。
3. **文献名称**：*Urinary NID2 methylation as a non-invasive biomarker for bladder cancer detection*
**作者**：Renard et al.
**摘要**：验证了尿液样本中NID2甲基化检测对膀胱癌诊断的高敏感性和特异性，提出其可辅助传统细胞学检查以提高准确性。
---
这些研究均涉及NID2抗体在基因表达、蛋白定位或表观遗传学分析中的应用，聚焦于癌症诊断及分子机制探索。
Nidogen-2 (NID2), also known as osteonidogen, is a basement membrane glycoprotein critical for maintaining extracellular matrix (ECM) stability. It interacts with key ECM components like laminins and collagen IV, facilitating tissue organization and cell signaling. The NID2 antibody, a tool to detect this protein, has gained attention in biomedical research, particularly in cancer studies.
NID2 is structurally characterized by three globular domains and a central linker region, enabling its role in bridging ECM networks. While traditionally studied in developmental contexts, recent research highlights its dual role in cancer progression. Some studies suggest NID2 promotes tumor invasion and metastasis by modulating ECM remodeling and activating oncogenic pathways (e.g., EMT). Conversely, other evidence indicates tumor-suppressive effects in specific cancers, possibly through ECM stabilization. This functional dichotomy has sparked debates about its context-dependent roles in tumor microenvironments.
Clinically, NID2 antibodies are explored as diagnostic biomarkers. Hypermethylation of the NID2 gene and its protein overexpression have been detected in urine samples of bladder cancer patients, showing diagnostic promise. Similar investigations extend to ovarian, breast, and colorectal cancers. Beyond oncology, NID2 dysregulation is linked to kidney diseases and cardiovascular disorders, though these areas remain understudied. Current challenges include standardizing detection methods and clarifying NID2's precise mechanisms across diseases. Ongoing research aims to validate its therapeutic potential and biomarker reliability in multi-omics frameworks.
×
